GlassScriptPhysician profile
Gopinath Upamaka
NPI 1750385670
$9,359.61
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,957 · 2020: $117 · 2021: $81.49 · 2022: $204.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $4,831.30 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $3,811.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $280.45 | 2019-2020 | |
| Abbott Laboratories | $228.89 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $42.34 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $33.65 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.12 | 2020 | |
| Lundbeck LLC | $18.21 | 2019 | |
| Pfizer INC. | $15.41 | 2019 | |
| Esperion Therapeutics, INC. | $15.20 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.19 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gopinath Upamaka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.